Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Acquires C$51,332.82 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh purchased 22,222 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was acquired at an average price of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Stock Up 0.8 %

FRX stock traded up C$0.12 during midday trading on Tuesday, hitting C$14.32. 300 shares of the company’s stock were exchanged, compared to its average volume of 754. The firm has a 50 day moving average price of C$13.50 and a 200-day moving average price of C$12.59. Fennec Pharmaceuticals Inc. has a 12-month low of C$9.27 and a 12-month high of C$15.43. The stock has a market capitalization of C$387.21 million, a price-to-earnings ratio of -14.04 and a beta of 0.35. The company has a current ratio of 3.29, a quick ratio of 10.17 and a debt-to-equity ratio of 881.09.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. The company had revenue of C$13.25 million during the quarter, compared to the consensus estimate of C$12.88 million. On average, analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.